ASCO: AstraZeneca wants to challenge rivals for immunotherapy class
This article was originally published in Scrip
There was no cutting-edge data from AstraZeneca or its biotech business MedImmune at this year’s ASCO, the big annual US cancer research meeting. That was made clear in advance of the Chicago conference. (scripintelligence.com May 16, 2013)
You may also be interested in...
Using Baxter’s Advate drug as a preventative therapy helped significantly reduce bleeding incidents in a yearlong study.
Mylan CEO Heather Bresch said she is looking to do a sizable deal that helps the US generic and specialty drug maker better compete in a consolidating field of rivals.
Biogen Idec CEO George Scangos is frank about his ambitions to dominate the market for hemophilia therapies, an opportunity he compares to the big biotech’s lead treating multiple sclerosis.